Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERADICATE-HF
NL-OMON50595Phase 2Recruiting
- Sponsor
- Toronto General Hospital
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and heart failure (HF) comparing Ertugliflozin with Placebo (2 arms). Primary endpoints: Persistent proximal renal tubular natriuretic effect, Fractional excretion of sodium and 3 more. Started May 2019; status: recruiting.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)
Beyond the preview
Go deeper on NL-OMON50595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50595.